vs

Side-by-side financial comparison of Karat Packaging Inc. (KRT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $115.6M, roughly 1.8× Karat Packaging Inc.). Karat Packaging Inc. runs the higher net margin — 5.9% vs -62.0%, a 67.9% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 13.7%). Karat Packaging Inc. produced more free cash flow last quarter ($15.1M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 10.0%).

Karat Packaging Inc. is a specialty manufacturer and distributor of disposable foodservice packaging products. Its offerings include paper and plastic cups, food containers, cutlery, lids, and custom branded solutions, serving restaurant chains, cafes, catering operators, and retail foodservice clients primarily across North America.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

KRT vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.8× larger
RARE
$207.3M
$115.6M
KRT
Growing faster (revenue YoY)
RARE
RARE
+12.2% gap
RARE
25.9%
13.7%
KRT
Higher net margin
KRT
KRT
67.9% more per $
KRT
5.9%
-62.0%
RARE
More free cash flow
KRT
KRT
$115.9M more FCF
KRT
$15.1M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
10.0%
KRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KRT
KRT
RARE
RARE
Revenue
$115.6M
$207.3M
Net Profit
$6.8M
$-128.6M
Gross Margin
34.0%
Operating Margin
7.3%
-54.7%
Net Margin
5.9%
-62.0%
Revenue YoY
13.7%
25.9%
Net Profit YoY
21.3%
3.5%
EPS (diluted)
$0.34
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRT
KRT
RARE
RARE
Q4 25
$115.6M
$207.3M
Q3 25
$124.5M
$159.9M
Q2 25
$124.0M
$166.5M
Q1 25
$103.6M
$139.3M
Q4 24
$101.6M
$164.6M
Q3 24
$112.8M
$139.5M
Q2 24
$112.6M
$147.0M
Q1 24
$95.6M
$108.8M
Net Profit
KRT
KRT
RARE
RARE
Q4 25
$6.8M
$-128.6M
Q3 25
$7.3M
$-180.4M
Q2 25
$10.9M
$-115.0M
Q1 25
$6.4M
$-151.1M
Q4 24
$5.6M
$-133.2M
Q3 24
$9.1M
$-133.5M
Q2 24
$9.1M
$-131.6M
Q1 24
$6.2M
$-170.7M
Gross Margin
KRT
KRT
RARE
RARE
Q4 25
34.0%
Q3 25
34.5%
Q2 25
39.6%
Q1 25
39.3%
Q4 24
39.2%
Q3 24
38.6%
Q2 24
38.5%
Q1 24
39.3%
Operating Margin
KRT
KRT
RARE
RARE
Q4 25
7.3%
-54.7%
Q3 25
6.9%
-106.9%
Q2 25
13.3%
-64.8%
Q1 25
7.5%
-102.6%
Q4 24
7.2%
-74.3%
Q3 24
10.0%
-94.6%
Q2 24
9.9%
-79.1%
Q1 24
8.4%
-151.9%
Net Margin
KRT
KRT
RARE
RARE
Q4 25
5.9%
-62.0%
Q3 25
5.9%
-112.8%
Q2 25
8.8%
-69.0%
Q1 25
6.2%
-108.5%
Q4 24
5.5%
-80.9%
Q3 24
8.1%
-95.7%
Q2 24
8.1%
-89.5%
Q1 24
6.4%
-156.8%
EPS (diluted)
KRT
KRT
RARE
RARE
Q4 25
$0.34
$-1.28
Q3 25
$0.36
$-1.81
Q2 25
$0.54
$-1.17
Q1 25
$0.32
$-1.57
Q4 24
$0.28
$-1.34
Q3 24
$0.45
$-1.40
Q2 24
$0.45
$-1.52
Q1 24
$0.31
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRT
KRT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$37.9M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$149.4M
$-80.0M
Total Assets
$287.7M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRT
KRT
RARE
RARE
Q4 25
$37.9M
$421.0M
Q3 25
$44.0M
$202.5M
Q2 25
$57.0M
$176.3M
Q1 25
$56.3M
$127.1M
Q4 24
$59.9M
$174.0M
Q3 24
$60.4M
$150.6M
Q2 24
$52.1M
$480.7M
Q1 24
$46.7M
$112.3M
Stockholders' Equity
KRT
KRT
RARE
RARE
Q4 25
$149.4M
$-80.0M
Q3 25
$154.5M
$9.2M
Q2 25
$155.8M
$151.3M
Q1 25
$153.3M
$144.2M
Q4 24
$155.6M
$255.0M
Q3 24
$157.3M
$346.8M
Q2 24
$157.7M
$432.4M
Q1 24
$154.4M
$140.3M
Total Assets
KRT
KRT
RARE
RARE
Q4 25
$287.7M
$1.5B
Q3 25
$302.8M
$1.2B
Q2 25
$321.0M
$1.3B
Q1 25
$312.2M
$1.3B
Q4 24
$294.5M
$1.5B
Q3 24
$306.8M
$1.5B
Q2 24
$310.7M
$1.6B
Q1 24
$279.0M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRT
KRT
RARE
RARE
Operating Cash FlowLast quarter
$15.4M
$-99.8M
Free Cash FlowOCF − Capex
$15.1M
$-100.8M
FCF MarginFCF / Revenue
13.1%
-48.6%
Capex IntensityCapex / Revenue
0.2%
0.5%
Cash ConversionOCF / Net Profit
2.26×
TTM Free Cash FlowTrailing 4 quarters
$33.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRT
KRT
RARE
RARE
Q4 25
$15.4M
$-99.8M
Q3 25
$982.0K
$-91.4M
Q2 25
$9.8M
$-108.3M
Q1 25
$7.7M
$-166.5M
Q4 24
$8.3M
$-79.3M
Q3 24
$19.5M
$-67.0M
Q2 24
$13.7M
$-77.0M
Q1 24
$6.6M
$-190.7M
Free Cash Flow
KRT
KRT
RARE
RARE
Q4 25
$15.1M
$-100.8M
Q3 25
$736.0K
$-92.7M
Q2 25
$9.6M
$-110.7M
Q1 25
$7.6M
$-167.8M
Q4 24
$8.0M
$-79.5M
Q3 24
$19.2M
$-68.6M
Q2 24
$13.4M
$-79.0M
Q1 24
$6.4M
$-193.9M
FCF Margin
KRT
KRT
RARE
RARE
Q4 25
13.1%
-48.6%
Q3 25
0.6%
-58.0%
Q2 25
7.7%
-66.5%
Q1 25
7.4%
-120.5%
Q4 24
7.9%
-48.3%
Q3 24
17.0%
-49.2%
Q2 24
11.9%
-53.7%
Q1 24
6.7%
-178.2%
Capex Intensity
KRT
KRT
RARE
RARE
Q4 25
0.2%
0.5%
Q3 25
0.2%
0.8%
Q2 25
0.1%
1.5%
Q1 25
0.1%
1.0%
Q4 24
0.2%
0.1%
Q3 24
0.3%
1.2%
Q2 24
0.2%
1.4%
Q1 24
0.2%
3.0%
Cash Conversion
KRT
KRT
RARE
RARE
Q4 25
2.26×
Q3 25
0.13×
Q2 25
0.89×
Q1 25
1.21×
Q4 24
1.47×
Q3 24
2.14×
Q2 24
1.50×
Q1 24
1.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KRT
KRT

Segment breakdown not available.

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons